Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2006

01-07-2006 | Preclinical study

Comparison of HER2 status between primary tumor and disseminated tumor cells in␣primary breast cancer patients

Authors: Erich F. Solomayer, Sven Becker, Graziella Pergola-Becker, Robert Bachmann, Bernhard Krämer, Ulrich Vogel, Hans Neubauer, Diethelm Wallwiener, Jens Huober, Tanja N. Fehm

Published in: Breast Cancer Research and Treatment | Issue 2/2006

Login to get access
Metadata
Title
Comparison of HER2 status between primary tumor and disseminated tumor cells in␣primary breast cancer patients
Authors
Erich F. Solomayer
Sven Becker
Graziella Pergola-Becker
Robert Bachmann
Bernhard Krämer
Ulrich Vogel
Hans Neubauer
Diethelm Wallwiener
Jens Huober
Tanja N. Fehm
Publication date
01-07-2006
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2006
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-005-9147-y

Other articles of this Issue 2/2006

Breast Cancer Research and Treatment 2/2006 Go to the issue

Epidemiology

XPD Common Variants and their Association with Melanoma and Breast Cancer Risk

Epidemiology

Population-based mammography screening results in substantial savings in treatment costs for fatal breast cancer

Epidemiology

Interrelationships between serum leptin, IGF-1, IGFBP3, C-peptide and prolactin and breast cancer risk in young women

Preclinical study

Identification of BAF57 mutations in human breast cancer cell lines

Clinical trial

Effects of raloxifene on sex steroid hormones and C-telopeptide in postmenopausal women with primary breast cancer

Preclinical study

AFPep: an anti-breast cancer peptide that is orally active
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits